Work Group Recap 1 of 10 August 2021 Virtual Interim Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at http://www.ncpdp.org/members/members_wg_info.aspx?wgid=wgmc.

Work Group 1 Telecommunication

DERFs/ECLs Reviewed:
- DERF 001809/Emergency ECL 000339 was recommended to MC to approve as modified.
- DERF 001810/Emergency ECL 000340 was recommended to MC to approve as modified.
- DERF 001820/ECL 000344 was withdrawn by the submitter.
- DERF 001821 was approved.
- DERF 001822/ECL 000345 was recommended to MC to approve as modified.
- DERF 001835 was pended to the WG9 PDMP Task Group.
- DERF 001836/ECL 000350 was recommended to MC to approve as modified.
- DERF 001837/ECL 000351 was withdrawn by the submitter.

Task Groups:
- The Telecommunication FAQ Task Group reviewed one FAQ from the WG1 Coordination of Benefits Task Group and one FAQ from WG1 Clinical and Safety Edits Task Group for publication in the Telecommunication Version D and Above Questions, Answers and Editorial Updates. They created an FAQ for lowercase data and COB reversals and reconciliation IDs. They reviewed three DERFs from other task groups, discussed negative total amount paid situations and disbanded the Insulin Pen Packaging Claim Adjudication Sub-Task Group.
  - The FAQ Controlled Substance Guidance Update Sub-Task Group reported Version 13 of Recommended Use of Quantity Prescribed (460-ET) in NCPDP Telecommunication Standards Version D.0 was published May 20, 2021. The task group is on hiatus pending any questions on the white paper or related issues.
  - The FAQ Insulin Pen Packaging Claim Adjudication Guidance Sub-Task Group recommendation was approved in May, so the sub-task group disbanded.
- The P and C/WC Monitoring, Billing and Education Task Group presented legislative and regulatory developments from the last quarter and emailed notice of several Workers’ Compensation regulatory changes to NCPDP members.
- The Coordination of Benefits Task Group reviewed and answered two questions of which one was in response to a member inquiry and published in the task group’s FAQ document. The other question was approved with modification for publication in the Telecommunication Version D and Above Questions, Answers and Editorial Updates. They created a DERF requesting a new reject code. The task group reviewed the Payer Sheet Template and identified recommendations for changes for Section 4.1 and additions to Section 2.6.3 to send to the SNIP Committee.
- The Information Reporting Problems Task Group reported updates to the Nx reports None and Proxy Delete form are available as of 5/13/2021. The task group did not meet this quarter.
- The Post Adjudication Task Group did not meet this quarter.
- The Definition of a Valid Prescriber Task Group is working on updates to the provider information in the Telecommunication Version D and Above Questions, Answers and Editorial Updates.
• The **Eligibility Verification Enhancements Task Group** did not meet this quarter.
• The **Benefit Integration Task Group** continues to modify the Benefit Integration Implementation Guide and schema to include benefit synchronization where appropriate. They also met with the Digital Therapeutics Task Group and confirmed the Benefit Integration Standard can accommodate their use case.
• The **Standardized Subrogation Task Group** did not meet this quarter.
• The **Expand Dollar Fields Task Group** did not meet this quarter.
• The **Clinical and Safety Edits Task Group** withdrew DERF 001820/ECL 000344 and created a DERF for new ECL values for Professional Service Codes, Approved Message Codes and two new reject codes as a replacement. They also created guidance for the response fields for Safe Disposal.
• The **Point of Sale Rebate Review Task Group** modified DERF 001810/ECL 000340 to include two Approved Message Codes and modified the descriptions. The task group also decided to remove the Emergency Status on both DERF 001809/ECL 000339 and DERF 001810/ECL 000340.
• The **Telecommunication Agility Next Generation (TANG) Task Group** presented a recommendation that WG1 Telecommunication adopt the same extensibility rules for JSON that have already been defined for XML for SCRIPT, Specialized and Real-Time Prescription Benefit Standards. They continue to develop a high-level road map that transitions the Claim Billing and Eligibility transactions towards JSON.
• The **Pharmacy Product Locator Task Group** built specific use cases to identify problems to be solved, flushing out more details on the need for the tool and the benefits to the patient.
• The **Pharmacy Services Billing Task Group** collaborated with WG1 Clinical and Safety Edits Task Group on the use of DUR/Professional Service Codes for patient education use cases, completed review of the coordination of benefit claims, continued work on a gap analysis between the X12 837P transaction and the NCPDP Telecommunication Standard S1 transaction, continued work on use cases and established Parking Lot discussion topics.

Other Reportables:
• **DSMO Change Requests:** An update on the status of the DSMO Change Request 1201 (New Version of the Batch Standard), 1202 (New Standard - Subrogation Implementation Guide for Batch Standard) and 1208 (New Version of the Telecommunication Standard) was provided in the WG1 download materials. DNS is working on the NPRM in the background and is slated for September 2021.
• **MC REMS Workflow to Transaction Task Group, MC RTPB Standard Task Group and MC SNIP Task Group:** Recaps for these task groups were provided in the WG1 download materials.

New Business:
• The **WG1 Scope and Goals** were reviewed, modified and approved as modified.
• The **Biosimilars Forum** duplicate prior authorization use case was presented.

**Work Group 2 Product Identification**

DERFs Reviewed:
• DERF 001838 was approved.
• DERF 001839 was approved as modified.

Old Business:
• Chris Hui of the National Library of Medicine (NLM) provided an update on RxNorm and DailyMed.

Task Groups:
• The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or to the release of new products. The task group:
Reviewed and submitted to WG2 for adjudication one new QUIC form (see final adjudication determination by the Work Group in this report):

- QUIC #202102 Jazz RYLAEZ

Reviewed four products via email and one during task group calls for verification of the package size or billing unit to list within the drug data compendia files.

Finalized and sent letter to CMS re: Reference to 8-digit NDC in Transparency in Coverage Final Rule (CMS-9915-F)

Completed and submitted a DERF to address the removal of the Billing Unit Decision Tree from the Billing Unit Request page of the Standards microsite of the NCPDP website.

Completed and submitted a DERF to update to FAQ 7.5 HOW DO I CONVERT A GTIN12, OR GTIN14, TO A UPC TO CREATE AN NCPDP 11-DIGIT UPC? in the NCPDP Product Identifiers Standard Implementation Guide.

Began to discuss the transition of the primary identifier for medical devices in the compendia files from the NDC or NHRIC to the UDI.

For April through June 2021, 2,601 new SPL Billing Unit Index files were generated with one changed SPL Billing Unit Index file based on the files received by the FDA from the compendia. The compendia group has reconciled 10 of the 11 NDCs with discrepancies.

- The Naming Standards for Drugs, Biologics and Biosimilars Task Group did not meet this quarter.
- The Outsourcing Facility Task Group did not meet this quarter.

Other Reportables:
- MC REMS Workflow to Transaction Task Group, MC NDC Scarcity Task Group and MC Digital Therapeutics Task Group: Recaps for these task groups were provided in the WG2 download materials.

New Business:
- New QUIC Form Review and Final Adjudication:
  - QUIC ##202102 Jazz RYLAEZ
    - BU = ML per 5.2.2 of the BUS with a package size of 0.5mL x number of vials dispensed.
    - 1.5mL for 3 vials (68727-900-03).
- WG2 2021-2022 Scope and Goals were reviewed, modified and approved as modified.
- Richard Brook of Change Healthcare provided an update on the Strategic Planning Committee’s Manufacturer Advisory Committee.

Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards

DERFs/ECLs Reviewed:
- DERF 001840/ECL 000352 was recommended to MC to approve as modified.
- DERF 001841 was approved.

Task Groups:
- The Manufacturer Rebate Standard Task Group discussed challenges with rebills and ways to improve the data. Jeff Albright gave a presentation about the task group’s discussion items.
- The Medical Rebate Standard Task Group did not meet this quarter.

New Business:
- The WG7 2021-2022 Scope and Goals were reviewed and approved.

Work Group 9 Government Programs

DERFs/ECLs Reviewed:
- DERF 001828 was pended.
DERF 001842/Emergency ECL 000353 was recommended to MC to approve as modified.

Task Groups:

- The **Government Programs Encounter Reporting Standard Task Group** made modifications to the draft implementation guide and supporting documents for DERF 001828 to be presented at work group.
- The **Hospice Task Group** finalized “Hospice Nx Processing Guidelines for Part D Plans” document, developed DERF 001842/Emergency ECL 000353 requesting four new reject codes and reviewed and finalized the Hospice Nx Payer Sheet.
- The **Prescription Drug Monitoring Programs Task Group** continued monitoring state PMP activity and updated the [State PMP Tracking Document](#), which was approved by WG9.
- The **Medicare Part D Frequently Asked Questions Task Group** worked with the Medicaid FAQ Task Group to review and modify a question regarding Medicare-Medicaid Plan (MMP) and Part D drug rejections. The question and response were approved for publication in the Medicare Part D FAQ document. The task group also received a question regarding Part B COB claims processing and is awaiting a response from CMS.
- The **Medicaid Frequently Asked Questions Task Group** worked with the Medicare Part D FAQ Task Group to review and modify a question regarding MMP and Part D drug rejections. The question and response were approved for publication in the Medicaid FAQ document.
- The **Coordination of Benefits Contractor (COBC)/Benefits Coordination and Recovery Center (BCRC) Task Group** reviewed the annual full replacement file, submitted change requests related to both the annual and daily files, repurposed the Chapter 14 Sub-Task Group and continued reviewing the COB Industry Updates Document – Plan Communication Users Guide (PCUG).
  - The **Clarify Chapter 14 Sponsor Requirements for COB Time Frames Sub-Task Group** completed the review of feedback received from the Standardization Committee Chairs and submitted Chapter 14 modifications and recommendations to CMS for review.
  - The **Medicare Part D Section 111 Issues and Questions Sub-Task Group** completed the review of the Proposed Rule for CMPs, created a contact list for Section 111 Responsible Reporting Entities (RRE) and Part D plans and created an FAQ document to help Section 111 Responsible Reporting Entities (RRE) and Part D plans understand the reporting process. The sub-task group moved to a bi-weekly call cadence.
- The **Medicare Financial Information Reporting (FIR) Task Group** created a proposal for FIR modifications for submission to CMS for approval. The task group moved to a weekly call cadence.
- The **Medicare Prescription Drug Event (PDE) Task Group** reviewed new and open questions which were submitted to CMS for review. The task group discussed options of how to better engage with CMS to obtain answers to submitted questions.
- The **340B Task Group** held a discussion with the Medicaid FAQ Task Group and New York State Medicaid agency regarding an inquiry from Medicaid that impacted both task groups.
- The **Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group** did not meet this quarter.

New Business:

- The **WG9 2021-2022 Scope and Goals** were reviewed, modified and approved as modified.

**Work Group 10 Professional Pharmacy Services**

Task Group Recaps:

- The **WG14/WG10 Standardized Medication Profile Task Group** completed and approved the draft Standardized Medication Profile White Paper which was presented to the HL7® Pharmacy Work Group on 03/01/2021. The white paper identifies and defines the components for
development of an interoperable medication profile standard. The task group prepared and submitted the Notice of Intent to Ballot to HL7®. The HL7® ballot period was in May 2021. The white paper passed HL7® May 2021 ballot, and all the comments were reconciled. NCPDP Standardization Co-Chairs had some questions, and those questions were reconciled. Margaret Weiker worked with HL7® to jointly publish the white paper. NCPDP published the paper in July 2021.

- The **Identification of Social Determinants of Health Task Group** started working on a draft white paper. They drafted an outline and started working on the introduction section.
- The **MTM and Pharmacist Clinical Services Task Group** reported the HL7® Technical Steering Committee completed reviewing the NCPDP/HL7® Pharmacist eCare Plan C-CDA template and Fast Healthcare Interoperability Resources (FHIR®) Implementation guides. The HL7® Technical Steering Committee approved the publication. HL7® is on track with FHIR® release 4 being published – will be jointly published to ANSI. HL7® balloting will be in September for FHIR® release 5. For the CMR Summary FHIR® wrapper, the task group created a draft Project Scope Statement to submit to HL7® to create a FHIR® Release 4 version. After review, the statement will be submitted to HL7® Pharmacy Work Group in September. For the Beneficiary Level Report (BLR), the task group continues to work on a guidance document recommending a BLR standard for exchange between the provider of the MTM services to the MAPD or PDP including identification of NCPDP and or HL7® standards.
- The **ml White Paper Task Group** did not meet this quarter.
- The **Universal Medication Schedule White Paper Task Group** did not meet but will continue to engage Mike Wolf, the principal investigator and advocate for UMS, in establishing strategies for revision of the white paper.
- The **Pharmacogenomics Task Group** began looking at various educational opportunities such as webinars and drafting a white paper. They created a PGx use cases document. The task group had a presentation by Kim Roberts from Pharmacy HIT on use of LOINC codes for PGx. The task group had a presentation by James Hoffman from St Jude’s highlighting the Clinical Pharmacogenomics Implementation Consortium (CPIC®) Informatics. The task group will continue collaboration with other organizations to identify current processes and standards for PGx and see where NCPDP can assist with the gaps.

**Other Reportables:**

- **WG18 Specialty Requirements for ePrescribing Task Group**, **WG14 Consultant Pharmacist Interoperability Task Group**, and **WG1 Pharmacy Services Billing Task Group**: Recaps for these task groups were provided in the WG10 download materials.

**New Business:**

- The **WG10 2021-2022 Scope and Goals** were reviewed, modified and approved as modified.

**Work Group 11 ePrescribing & Related Transactions**

**DERFs Reviewed:**

- DERF 001831 was approved as modified.
- DERF 001843/ECL 000354 was recommended to MC to approve.
- DERF 001844 was approved.
- DERF 001845 was approved.
- DERF 001846 was approved.
- DERF 001847 was approved as modified.
- DERF 001848 was approved.
• DERF 001849 was pended to the WG11 Implementation of Structured and Codified Sig Task Group.
• DERF 001850 was approved as modified.
• DERF 001851 was approved.
• DERF 001852 was approved as modified.
• DERF 001853 was approved.

Task Groups:
• The Dispensed Medication Reporting Task Group did not meet this quarter.
• The ePrescribing Regulatory Task Group did not meet this quarter.
• The Formulary and Benefit Task Group continued working on recommendations for the Formulary and Benefit Implementation Recommendations document for the NCPDP Formulary and Benefit Standard Version 53.
• The Implementation of Structured Sig Task Group brought forth DERF 001849. They also answered questions that were submitted.
• The Pharmacy to Pharmacy Prescription Transfer Task Group brought forth DERF 001845 to allow the retraction/withdrawal of RxTransfer messages. They also received approval for the inclusion of a new FAQ in the SCRIPT Implementation Recommendations document.
• The Prior Authorization Workflow to Transactions Task Group brought forth DERFs 001843/ECL 000354 and 001851.
• The WG11/WG14 RxFill Task Group received approval for updated guidance for the use of the RxFill message for the SCRIPT Implementation Recommendations document.
• The SCRIPT Implementation Recommendations Task Group brought forth DERFs 001831, 001846, 001847 and 001848.
  o The Insulin Pump Use Sub-Task Group was disbanded.
  o The RxChange Guidance Review Sub-Task Group brought forth DERF 001850.
• The XML Task Group continued to work on looking at the medication types in their process to streamline the schema. The task group reviewed and provided recommendations on all submitted DERFs impacting the schema.

Other Reportables:
• An Electronic Prescriptions for Controlled Substances (EPCS) update was provided.
• SCRIPT Version 2017071 NSC-11 certified members were recognized.
• An RxNorm and DailyMed update was provided.

New Business:
• The WG11 2021-2022 Scope and Goals were reviewed, modified and approved as modified.
• The Biosimilars Forum duplicate prior authorization use case was presented.

Work Group 14 Long Term and Post Acute Care (LTPAC)

Task Groups:
• The LTPAC Billing Issues Task Group did not meet this quarter.
• The Consultant Pharmacist Interoperability Task Group decided to update the current C-CDA guidance document, Consultant Pharmacist Consult Note v1.0: Guidance on the Use of the HL7® CDA Consolidated Templates for Clinical Notes R2.1 Consult Note, making it consistent with the FHIR® Consultation Note Resource Profile.
• The Long Term and Post-Acute Care ePrescribing Task Group discussed topic from Long Term and Post Acute Care Electronic Communications Synchronization Opportunity Review (INSYNC) Task Group regarding should the prescriber also get an RxFill after the facility sends a Resupply to
the pharmacy. It was determined the RxFill should still go to the facility only since it is just an inventory request. If the prescriber does want a copy, they can use the RxFillIndicatorChange or the new MessageIndicatorFlag for RxFill copies.

- The **WG14/WG10 Standardized Medication Profile Task Group** completed their gap analysis of the NCPDP and HL7® standards and determined to use the HL7® FHIR® standard and received approval for the Standardized Medication Profile White Paper. The white paper has been jointly published with HL7®.
- The **WG11/WG14 RxFill Task Group** received approval for updated guidance for the use of the RxFill message for the SCRIPT Implementation Recommendations document.

Other Reportables:
- Received a LTPAC industry update.

New Business:
- **WG14 2021-2022 Scope and Goals** were reviewed, modified and approved as modified.

**Work Group 18 Specialty Pharmacy**

Task Group Recaps:
- The **Specialty Requirements for ePrescribing Task Group** monitored the ballot process for the jointly developed Specialty Implementation Guide with HL7®. The HL7® ballot reconciliation is complete and passed at the Pharmacy Work Group. The task group will continue pursuing status updates for the Specialty Medication Enrollment Standard during the next quarter.
- The **Specialty Pharmacy Data Exchange Task Group** continued working on the ‘Performance Metrics’ including structure. The task group discussed possible beta implementation of the Data Reporting Standard – have pharmacy partner willing to pilot; need manufacturer partner. Task group leads participated in NASP Technology Subcommittee meetings.
- The **Benefit Coverage Identification Task Group** created and reviewed a flow chart regarding how information can be exchanged and the information obtained from RTPB transaction. They worked on a survey on how much time is spent on each activity. The task group is looking to do a pilot of maybe 20 individuals (WG18 members or just the task group) and then define and sharpen the information from the pilot to be able to create a more accurate survey for a larger population. Possible pilot with providers to include procedure codes on 270/271 to showcase the value and return on investment.
- The **Patient Consent Task Group** discussed three task group business cases (Unsolicited Consent, Consent Notification During the Encounter and Consent Request/Response). The group decided to prioritize work on the two messaging use cases (1. Unsolicited Consent and 3. Consent Request/Response). The group will define the electronic exchange specifications for Use Cases 1 and 3 in a manner that enables the result to be used in conjunction with the NCPDP Specialty Rx FHIR® Implementation Guide.
- The **Facilitation Access to Specialty Products Task Group** developed a recommendations paper providing information to manufacturers, prescribers, payers and pharmacies regarding hub services and limited distribution products. The paper was reviewed and approved for publication after several minor editorial changes identified during the May Work Group. The task group is awaiting updated visuals from NCPDP marketing before publishing. It was also noted that the Standardization Committee had returned comments on the white paper that need to be addressed and that the TG would be reviewing and revising.

Other Reportables:
• **WG10 Identification of Social Determinants of Health Task Group, WG11 Prior Authorization Workflow-to-Transaction Task Group, MC REMS Workflow-to-Transaction Task Group and MC Real Time Prescription Benefit Standard Task Group:** Recaps for these task groups were provided in the [WG18 download materials](#).

**New Business:**
- Richard Brook of Change Healthcare provided an update on the Strategic Planning Committee’s Manufacturer Advisory Committee.
- The **WG18 2021-2022 Scope and Goals** were reviewed, modified and approved as modified.

### Work Group 45 External Standards Assessment and Implementation Guidance

**Old Business:**
- Industry updates were provided for WEDI, NCPDP SNIP, CAQH CORE and X12.

**Task Groups:**
- The **Pharmacy and/or Combination ID Card Task Group** continued reviewing the Pharmacy and/or Combination ID Implementation Guide and is performing outreach around the Consolidated Appropriations Act of 2021.
- The **834/835 FAQ Task Group** did not meet this quarter.
- The **Document Revisions Task Group** did not meet this quarter.
- The **DSMO Task Group** received no DSMO requests for review.

**New Business:**
- The **WG45 2021-2022 Scope and Goals** were reviewed, modified and approved as modified.

### MC Maintenance and Control – DERF Harmonization

**New Business:**
- DERF 1835 was referred to Work Group 9 Government Programs for review for harmonization.
- The following DERFs were highlighted to create awareness:
  - DERF 001828
  - DERF 001831
  - DERF 001836/ECL 000350
  - DERF 001852

## MC Maintenance and Control

**Ballot Adjudicated:**
- **Ballot WGMC0010R** - Enhancements to the Real-Time Prescription Benefit Standard Implementation Guide Version 12 is considered a valid ballot having received the required 60% of Consensus Group votes and received 75% approval rating on the recirculation ballot. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

**DERFs/ECLs:** 19 new and 7 pended DERFs/ECLs were reviewed (see WG1, WG2, WG7, WG9 and WG11).
- DERF 001809/Emergency ECL 000339 was approved as modified.
- DERF 001810/Emergency ECL 000340 was approved as modified.
- DERF 001820/ECL 000344 was withdrawn by the submitter.
- DERF 001821 was approved.
- DERF 001822/ECL 000345 was approved as modified.
- DERF 001828 was pended.
- DERF 001831 was approved as modified.
• DERF 001835 was pended.
• DERF 001836/ECL 000350 was approved as modified.
• DERF 001837/ECL 000351 was withdrawn by the submitter.
• DERF 001838 was approved.
• DERF 001839 was approved as modified.
• DERF 001840/ECL 000352 was approved as modified.
• DERF 001841 was approved.
• DERF 001842/Emergency ECL 000353 was approved as modified.
• DERF 001843/ECL 000354 was approved.
• DERF 001844 was approved.
• DERF 001845 was approved.
• DERF 001846 was approved.
• DERF 001847 was approved as modified.
• DERF 001848 was approved.
• DERF 001849 was pended.
• DERF 001850 was approved as modified.
• DERF 001851 was approved.
• DERF 001852 was approved as modified.
• DERF 001853 was approved.

Old Business:
• Received updates on:
  o Board of Trustees
  o SNIP Committee
• Updates for the following were provided in the MC download materials:
  o HIPAA
  o DSMO Change Request System (CRS) Requests No. 1201, 1202 and 1208

Task Groups:
• The Education/Legislation and Regulations Task Group submitted comments to the Office of the National Coordinator for Health Information Technology regarding the Health Information Technology Advisory Committee recommendation to use RxNorm over the National Drug Code.
• The Emergency Preparedness Task Group updated guidance document to incorporate the CDC’s recommendation for a third dose of vaccine for immunocompromised patients.
• The X12 TR3 Comment Consolidation Task Group is on hiatus and did not meet this quarter.
• The Real Time Prescription Benefit Standard (RTPB) Task Group decided to “parking lot” any further discussion about enhancements to the standard for drug discount plan inquiries. The task group drafted two FAQs for the RTPB Implementation Recommendations document related to using Version 12 for drug discount plan inquiries. The task group agreed to recommend CMS recognize, via the rulemaking process, version 12 of the standard. They also decided to follow the SCRIPT/Specialized ECL implementation process for RTPB ECL implementation. The work group approved the two FAQs and the recommendation of the naming of Version 12.
  o The Consumer-Facing RTPB and Price Transparency Sub-Task Group discussed the data requirements for request and response transactions. The objective is to identify data requirements and then compare those requirements to existing internal and external standards.
• The Gender Transition Task Group submitted DERF 001853 to add new optional data element, Pronoun, to SCRIPT and Specialized to harmonize with HL7® and to identify an individual’s
preferred pronouns. The task group reviewed conditional gender codes with the WG11 Formulary and Benefit Task Group.

- The **Digital Therapeutics Task Group** reviewed the Benefit Integration Standard for a gap analysis. The task group finished updates to the *Background and Guidance for Using the NCPDP Standards for Digital Therapeutics* to incorporate the results of the gap analysis additional standards. The work group approved the updated document.

- The **NDC Scarcity Task Group** is on hiatus and did not meet this quarter. The task group requested an expansion of their scope to also address the issue of the expanded Product Service Identifier implementation in time to accommodate the Telecommunication Standard Version F6 implementation. The work group approved the expanded scope.

- The **Patient Identification Task Group** updated the *Universal Patient Identifier Guidance Document Version* to reflect the changes to the XML structure for communicating Universal Patient Identifiers (UPI) and add Real-Time Prescription Benefit Standard to list of standards able to communicate UPI. The work group approved the updated document.

- The **Definition and Use of Quantity and Day Supply Task Group** initiated work on creating discrete days supply related data elements. The task group determined that two FAQs are needed for the Telecommunication Version D.0 Editorial Guide. One is about whether Days Supply (405-D5) represents a single dispensing or the whole prescription, and the other is about estimating the value for Days Supply (405-D5) in Telecommunication Version D.0.

- The **2D Barcode Implementation Task Group** did not meet this quarter. The updated NCPDP GS1 DataMatrix white paper was published. The task group requested to disband, and the work group approved the request.

- The **REMS Workflow to Transactions Task Group** modified their scope and goals. The task group created a REMS functionality matrix to assist in identification of gaps. The work group approved the modified scope and goals.

- The **NCPDP Standards Message Structure Harmonization Task Group** identified all NCPDP standards and their current format, stakeholders and work group and task group ownership. The task group also identified the pros/cons of moving to a modern format that aligns to the Telecommunication Standard JSON changes.

New Business:

- The **MC WG 2021-2022 Scope and Goals** were reviewed, modified and approved as modified.
- Richard Brook of Change Healthcare provided an update on the Strategic Planning Committee’s Manufacturer Advisory Committee.